semaglutide renal impairment dosing FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Semaglutide in patients with kidney
Description
Plateaus can happen because of water, digestion, routine changes, strength training, constipation, or normal adaptation
Concerning cutaneous manifestations, specifically bullous pemphigoid, retrospective analysis of over 9,000 patients treated in Japan (20092017) associated it with DPP-IV inhibitors, particularly vildagliptin (Kawaguchi et al., 2019)
The most common ones include mild nausea, bloating, or constipationusually short-lived and manageable
Teens who participated experienced 16% total body weight loss at 68 weeks while taking semaglutide
